Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects With Tenosynovial Giant Cell Tumour

NCT05417789 is registered in ClinicalTrials.gov with SynOx Therapeutics Limited as lead sponsor.

NCT NCT05417789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05417789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects With Tenosynovial Giant Cell Tumour
Lead sponsor
SynOx Therapeutics Limited
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 9, 2024
Completion date
September 30, 2030
Enrollment
128 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

tgct